Case Study: In Vitro Data
Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against
BA.1 and BA.2 Omicron SARS-CoV-2 Variants
Todos Medical is pleased to report that its majority-owned subsidiary 3CL Pharma, Ltd. announced that its mechanism-based 3CL protease inhibitors Tollovir® and Tollovid™ that target the active site of the 3CL protease showed robust inhibitory activity against the 3CL protease of the BA.1 and BA.2 strains of the Omicron SARS-CoV-2 variant of concern (VOC). Additionally, Tollovir and Tollovid showed inhibitory activity against the original wild-type SARS-CoV-2 strain, as well as the Alpha, Beta, Delta and Gamma VOCs. The results showed IC50 binding affinity of <5 for Tollovid and <1 for Tollovir for each of the different SARS-CoV-2 strains. The experiments were completed at Tel Aviv University in Israel.
“We are pleased to see that Tollovid and Tollovir have robust in vitro inhibitory activity against the mutated 3CL PRO BA1 BA2 omicron and multiple strains of SARS-CoV-2 Omicron. There was no loss of activity with our inhibitors because they target the catalytic active site of the 3CL protease, which has not mutated in any meaningful way,” said Dr. Dorit Arad, Chief Technology Officer of 3CL Pharma, Ltd. “We are now waiting on additional data from the extension phase of our ongoing Tollovir Phase 2a study for which we already announced data that demonstrates Tollovir use adds significant efficacy to the current standard of care of Remdesivir + dexamethasone. As we do this, we are beginning to receive case reports from physicians on the potential benefits of Tollovid and we are gathering this data as we plot our regulatory strategy to turn Tollovid into an OTC drug with claims for acute COVID, Long-COVID and pediatric COVID.”
3CL Protease Inhibitors found in Tollovid™ and Tollovir® target the active site of the 3CL protease and showed robust inhibitory activity against the 3CL protease of the
BA.1 and BA.2 strains of the Omicron SARS CoV-2 variant.